The introduction of cimetidine (Tagamet) by Smith, Kline & French (now SKB) in 1976 is a landmark event in the history of therapeutics. The drug heralded a revolution in the treatment of acid-peptic disorders, initiated an era of intense research and discovery benefiting all of gastroenterology, and resulted in unprecedented expansion of the pharmaceutical industry. A voluminous literature exists relating to the discovery, development, and use of cimetidine itself, and to the various other antiulcer drugs that have followed in its wake.'`What then are the landmarks during a period of two decades when cimetidine became the first billion dollar drug and antiulcer agents have exclusively occupied the position of the World's top selling drug?
H2 antagonists after cimetidine The cycle of breakthrough discovery followed by line extension is a fundamental characteristic of consumer products, including drugs. In the case of pharmaceutical industry, what are commonly, but rather unfairly, referred to as 'me-too drugs' provides the basis for refining a particular therapeutic class with respect to pharmacodynamics, pharmacokinetics, side effects, and patient tolerability. Ranitidine4 was introduced by Glaxo in 1981 as a more potent drug with a superior side effect profile and, backed by a skillful marketing campaign, superseded cimetidine as the world's most successful drug. The profile of the H2 antagonist sector emerging in the early 1980s conformed to the model that major markets can support four or five related drugs after which the return on development costs make further introductions commercially unattractive. In an attempt to radically change the profile of reversible antagonists, many companies sought to develop long acting inhibitors, either through an increase in half life or by non-competitive/ irreversible interaction with the receptor, to increase the duration of antisecretory cover. While this search went on, the pattern of use of marketed H2 antagonists was also changing because it was found that a single night time dose was as effective as multiple daily doses, at least in duodenal ulceration. It was also clear that existing compounds lacked efficacy in oesophageal ulceration. In contrast, many non-competitive H2 antagonists were extremely potent and displayed a prolonged duration of action in vivo at sub-maximal doses. For example, the most potent of these compounds ICI 162,846 showed pronounced antisecretory activity in humans 24 hours after dosing at 1-5 mg.'2 The other major factor in trying to market these compounds lay in counteracting the commercial threat posed by development of proton pump inhibitors (PPIs).
Both SKB (lupitidine) and Glaxo (lamptidine and loxtidine) were successful in taking long acting H2 antagonists into clinical trials. However, development of these compounds was stopped because of the occurrence of carcinoid lesions in rat long term toxicity studies. Loxtidine in particular was withdrawn from development amid considerable publicity.`' Adverse press in relation to target organ toxicity undoubtedly delayed the development and ultimate approval of the first PPI omeprazole. '4 In what became a highly commendable stance, Astra set about explaining the scientific basis of these lesions. Not only did this work facilitate regulatory approval of omeprazole but also led to advances in understanding the trophic role of gastrin and the pathobiology of the enterochromaffin-like (ECL) cell. '5 16 Proton pump inhibitors A year after the UK launch of cimetidine, the third in a series of mine stimulated acid secretion from isolated gastric mucosa and inhibited secretion induced by the intracellular mediator cAMP.'9 While it was clear that this inhibitor had not been discovered through the systematic pharmacological analysis that had characterised discovery of cimetidine, history has shown the therapeutic impact of this class of antisecretory drugs to be just as significant.
Omeprazole (Losec) was launched by Astra in 1989 after a tortuous and somewhat acrimonious development progamme. In contrast with cimetidine, the precise mechanism of action of the drug only emerged during the course of its development.20 This in turn enabled rationalisation of the extremely high efficacy and specificity of benzimidazole derivatives. Thus accumulation of the basic pro-drug in the secretory cannaliculus of the parietal cell is followed by acid conversion to reactive sulphenamides, which inactivate the H/K-ATPase by disulphide bonding to thiol groups in the extracellular domain of the enzyme.2' The restricted location of H/KATPases and the uniquely acidic environment of the gastric enzyme, combined with the pK/log D of the compound itself, impart a degree of specificity rarely encountered in medicinal chemistry.
Although the development of omeprazole was characterised by a reluctance to emphasise its ability to induce prolonged acid suppression, clinical success of the drug is clearly a direct consequence of its powerful and sustained antisecretory action. 22 During clinical trials, omeprazole produced faster rates of ulcer healing and healed ulcers resistant to H2 antagonists. Most significant, however, was the fact that omeprazole proved highly effective in moderate to severe reflux disease wherein the H2 blockers lacked efficacy.23 PPIs have also become the drugs of choice for combining with antibiotics to eradicate Helicobacter pylori, with Astra having set a precedent by gaining regulatory approval for the combination of omeprazole and an antibiotic. The success of cimetidine and ranitidine has now been emulated by omeprazole, which became the number one selling drug in Europe and third on the world list in 1994. Given that peak sales usually occur 10-12 years after launch, it is probable that the success of omeprazole will continue into the 21st century. Differences between the available PPIs have been claimed with respect to interaction with both the H/KATPase and cytochrome P450 enzyme systems. In the case of the proton pump, differences have been reported with respect to the number of cysteine binding sites, their effects on conformation and partial reactivity of the enzyme, rates of acid activation and thus onset of action, kinetics of reversal by scavenger mechanisms, and antisecretory potency in animals. 26 27 However, none of these differences would seem to have any significance for clinical efficacy because, at the recommended doses, antisecretory activity and ulcer healing rates are similar. PPIs are also capable of killing H pylori in vitroll but this property, at least as far as current drugs and formulations are concerned, is probably also irrelevant because the luminal concentrations achieved are negligible due to enteric coating. Whether lansoprazole or pantoprazole, if either, emerges as a clear second to omeprazole in the PPI sector rests on development strategy and safety issues such as selectivity/ tolerability and metabolism. Safety in terms of freedom from drug interactions was a major determinant in establishing market share in the H2 sector.
Pantoprazole24 (Byk-
Current issues and future therapy Although ulcer recurrence was an identifiable shortcoming of antisecretory therapy, clinical needs seemed to have been largely met towards the end of the 1980s with the availability of ranitidine and omeprazole. However two separate findings, a reduction in the frequency of ulcer relapse in patients receiving bismuth therapy29 and the discovery of an association between Campylobacter pylori infection and ulcer disease,30 resulted in what could give rise to a third major therapeutic category of antiulcer treatment. A once daily monotherapy inducing reliable eradication of H pylori would undoubtedly be a commercially attractive proposition,3' It is, however, interesting to note that H pylori was mentioned only twice among the replies we received from the 10 chief executive officers representing major drug companies with interests in antiulcer therapy to whom we wrote before preparing this leading article with the request to list, from their perspective, the three most important issues which currently affect this drug sector.
Certainly anti-H pylori monotherapy is some considerable way off. Moreover, such treatments will not impact the need for antisecretory therapy in patients with reflux oesophagitis, those with peptic ulcer and associated reflux, or to counteract the gastrointestinal side effects of NSAIDs. There is also uncertainty concerning the are also similar, including therapeutic equivalence and cost-benefit, specificity and side effects, long term tolerability and safety, as well as outright commercial issues such as market share, patent expiry, and generic competition. A major difference between the two, however, is the importance of self medication in treating acid-peptic disorders. Given that safety has been a prime factor in gaining regulatory approval for over the counter use of H2 blockers, eventual appearance of PPIs in this sector cannot be ruled out.
In extending the analogy between ulcer disease and essential hypertension, where there are eight classes of antihypertensives in current use, it would be surprising if H2 blockers and PPIs were the end of the story in treating acid-peptic disorders. There are no lack of clues on which to base a search for clinically relevant approaches, not least of which are the sensitivity of H pylori to agents other than antibiotics or the ameliorating effect of the gravid state. In closing, however, we return to the original stimulus for this article, namely the 20 year anniversary of the launch of cimetidine. It is a sobering thought that with peak sales of $200 million forecast before its launch, the antiulcer drug market has developed into a $10 billion per year industry contributing some $2 billion to the UK balance of payments. Perhaps it is most fitting, however, to close with a reminder of the name of the person responsible for initiating the whole story namely Sir James Black.36
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